Quality of life in patients with malignant pleural effusion treated with an indwelling pleural catheter in an emerging country
Carregando...
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2022
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER ESPANA
Citação
CLINICS, v.77, article ID 100063, 7p, 2022
Resumo
Background: The use of Indwelling Pleural Catheter (IPC) in the care of patients with Malignant Pleural Effusion (MPE) is well established, however studies involving public health systems of low and middle-income countries are still lacking. This study aimed to determine the effect of IPC on the respiratory symptoms and Quality of Life (QoL) of patients with MPE in the setting of a Brazilian public health system. Methods: From August 2015 to November 2019, patients with MPE underwent IPC placement and were prospec-tively followed. QoL and respiratory symptoms were assessed by the EORTC questionnaires (QLQ-30; LC13) and Visual Analogue Scale (VAS), respectively, at pre-treatment, 30 , and 60 days after IPC placement. Results: 56 patients were enrolled with 57 catheters inserted. The mean age was 63 (23???88) years, of which 17 (30%) were men and 39 (70%) were women. Breast 24 (42%) and lung 21 (37%) were the main primary neo-plasms. Cellulitis was the most common complication and all patients recovered with appropriate antimicrobial therapy. QoL did not change significantly over time, however, the VAS showed a significant improvement in dys-pnea (+1.2:-0.5; p = 0.001). Conclusion: IPC relieves respiratory symptoms without compromising the QoL, with a low complication rate. It represents a suitable option for patients with MPE and short LE in an emerging country.
Palavras-chave
Brazilian public health system, Indwelling pleural catheter, Life expectancy, Malignant pleural effusion, Quality of life
Referências
- AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
- Ahlner-Elmqvist M, 2009, PALLIATIVE MED, V23, P432, DOI 10.1177/0269216309104057
- Bausewein C, 2007, RESP MED, V101, P399, DOI 10.1016/j.rmed.2006.07.003
- Bertolaccini L, 2012, EJSO-EUR J SURG ONC, V38, P1161, DOI 10.1016/j.ejso.2012.08.021
- Brabo EP, 2006, QUAL LIFE RES, V15, P1519, DOI 10.1007/s11136-006-0009-9
- Cases E, 2009, ARCH BRONCONEUMOL, V45, P591, DOI 10.1016/j.arbres.2009.09.009
- CHERNOW B, 1977, AM J MED, V63, P695, DOI 10.1016/0002-9343(77)90154-1
- Davies HE, 2012, JAMA-J AM MED ASSOC, V307, P2383, DOI 10.1001/jama.2012.5535
- Diacon AH, 2000, AM J RESP CRIT CARE, V162, P1445, DOI 10.1164/ajrccm.162.4.2002030
- Efthymiou Christopher Andrew, 2009, Interact Cardiovasc Thorac Surg, V9, P961, DOI 10.1510/icvts.2009.211516
- Fortin M, 2015, J THORAC DIS, V7, P1052, DOI 10.3978/j.issn.2072-1439.2015.01.51
- Giesinger JM, 2011, J PALLIAT MED, V14, P904, DOI 10.1089/jpm.2011.0086
- Heffner JE, 2000, CHEST, V117, P79, DOI 10.1378/chest.117.1.79
- Instituto Brasileiro de Geografia e Estatistica, PESQ NAC SAUD 2019 I
- Janssen JP, 2007, LANCET, V369, P1535, DOI 10.1016/S0140-6736(07)60708-9
- Lorenzo MJ, 2014, PALLIATIVE MED, V28, P326, DOI 10.1177/0269216314521851
- (NCI) NCI, 2009, COMM TOX CRIT ADV EV
- Penz ED, 2014, CHEST, V146, P991, DOI 10.1378/chest.13-2481
- Petersen MA, 2009, J PALLIAT MED, V12, P1023, DOI 10.1089/jpm.2009.0108
- Preston NJ, 2013, PALLIATIVE MED, V27, P899, DOI 10.1177/0269216313486952
- Putnam JB, 1999, CANCER, V86, P1992, DOI 10.1002/(SICI)1097-0142(19991115)86:10<1992::AID-CNCR16>3.0.CO;2-M
- SANCHEZARMENGOL A, 1993, CHEST, V104, P1482, DOI 10.1378/chest.104.5.1482
- Tremblay A, 2006, CHEST, V129, P362, DOI 10.1378/chest.129.2.362
- van den Toorn LM, 2005, LUNG CANCER, V50, P123, DOI 10.1016/j.lungcan.2005.05.016
- Van Meter MEM, 2011, J GEN INTERN MED, V26, P70, DOI 10.1007/s11606-010-1472-0